References
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523
Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, Kobayashi T, Yoshida A, Yoshimura A (2009) Involvement of Th17 cells and the effect of anti-IL-6. Therapy in autoimmune uveitis. Rheumatology 48:347–354
Valentincic NV, de Groot-Mijnes JD, Kraut A, Korosec P, Hawlina M, Rothova A (2011) Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis 17:2003–2010
Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A (2011) Efficacy of tocilizumab in two patients with anti TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19:382–383
Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab and effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39:1294–1295
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adán, A., Llorenç, V., Mesquida, M. et al. Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 251, 2249–2250 (2013). https://doi.org/10.1007/s00417-012-2243-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-012-2243-x